Company / Return on Equity (ROE)
CRESCENT BIOPHARMA, INC. Return on Equity (ROE) History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-75.8%
FY2025
5-year range
-364.8% / 29.2%
FY2021-FY2025
Trend
-140.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
CRESCENT BIOPHARMA, INC. reports negative total equity of -75.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-75.8% in FY2025 with a 10-year CAGR of +288.9%.
Declined from -21.9% to -75.8% over the past 9 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- +288.9pp
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 140.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2014.
- Lowest return on equity (roe) in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -75.8% | -140.3% |
| FY2017 | -31.6% | -44.1% |
| FY2016 | -21.9% | +94.0% |
| FY2015 | -364.8% | -1350.1% |
| FY2014 | 29.2% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026